- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
The FDA is reviewing TAR-200 for approval, a process involving major pharmaceutical companies like Merck, AstraZeneca, and Pfizer in the oncology space.
3 reports, 1 independent
Updated Jul 18
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is reviewing TAR-200 for approval, a process involving major pharmaceutical companies like Merck, AstraZeneca, and Pfizer in the oncology space.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.Also in this story
- Ipsen received regulatory approval for Cabometyx, marking a competitive development with Merck in the renal cell carcinoma space.
- Iovance Biotherapeutics is evaluating its drug Amtagvi with Merck's Keytruda, potentially leading to FDA label expansion.
- Merck's product, Enflonsia, received approval from the FDA in the United States on August 28, 2025.
Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The entities involved
- FDA
-
Merck
public company in Indonesia
-
AstraZeneca
British-Swedish pharmaceutical company
-
Pfizer PFE
Czech company
Nothing else this week.
Related events
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- FDA and Pfizer are seeking regulatory approval for their products.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
Coverage
Newest first; wire copies grouped- ZacksJ&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal? Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion by
- ZacksHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results? AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer d
- Unknown outlet